Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

BACKGROUND: Half of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jingyi, Li, Xiaoqing, Zhou, Juan, Qiu, Dan, Zhang, Mengyao, Sun, Lan, Li, Shengwen Calvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117841/
https://www.ncbi.nlm.nih.gov/pubmed/37091182
http://dx.doi.org/10.3389/fonc.2023.1043244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117841/
https://www.ncbi.nlm.nih.gov/pubmed/37091182
http://dx.doi.org/10.3389/fonc.2023.1043244

Ejemplares similares